Q1 EPS Forecast for Edgewise Therapeutics Lowered by Analyst

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Equities researchers at Leerink Partnrs reduced their Q1 2025 EPS estimates for Edgewise Therapeutics in a research report issued on Monday, March 3rd. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.45) per share for the quarter, down from their prior forecast of ($0.40). The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics' Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($2.53) EPS.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.03).

EWTX has been the subject of several other research reports. Evercore ISI boosted their price target on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Tuesday, December 17th. Stifel Nicolaus initiated coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They issued a "hold" rating and a $30.00 target price for the company. Royal Bank of Canada reissued an "outperform" rating and set a $56.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday, March 4th. Scotiabank began coverage on Edgewise Therapeutics in a research note on Friday. They issued a "sector outperform" rating and a $50.00 price target for the company. Finally, Truist Financial upped their price objective on Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a "buy" rating in a research note on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $45.38.

Remove Ads

Edgewise Therapeutics Price Performance

Shares of Edgewise Therapeutics stock traded down $0.12 during trading on Wednesday, hitting $28.01. 2,167,322 shares of the company were exchanged, compared to its average volume of 1,044,137. The firm has a market capitalization of $2.67 billion, a P/E ratio of -18.67 and a beta of 0.22. The firm's fifty day moving average price is $26.77 and its 200 day moving average price is $27.88. Edgewise Therapeutics has a 1-year low of $14.90 and a 1-year high of $38.12.

Insider Transactions at Edgewise Therapeutics

In related news, insider Marc Semigran sold 29,709 shares of the company's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total value of $882,060.21. Following the transaction, the insider now directly owns 6,716 shares in the company, valued at approximately $199,398.04. This represents a 81.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Alan J. Russell sold 1,200 shares of Edgewise Therapeutics stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the completion of the sale, the insider now owns 14,863 shares of the company's stock, valued at $447,822.19. This trade represents a 7.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 164,545 shares of company stock worth $4,605,305 over the last quarter. Company insiders own 24.11% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its position in Edgewise Therapeutics by 5.4% during the fourth quarter. Baker BROS. Advisors LP now owns 6,155,940 shares of the company's stock worth $164,364,000 after buying an additional 315,881 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Edgewise Therapeutics by 9.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,983,940 shares of the company's stock worth $133,044,000 after purchasing an additional 425,421 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in Edgewise Therapeutics by 61.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company's stock worth $119,988,000 after buying an additional 1,704,757 shares in the last quarter. Braidwell LP grew its stake in Edgewise Therapeutics by 19.1% during the fourth quarter. Braidwell LP now owns 2,332,196 shares of the company's stock worth $62,270,000 after buying an additional 373,886 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C increased its holdings in Edgewise Therapeutics by 16.7% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,078,509 shares of the company's stock valued at $55,496,000 after buying an additional 297,503 shares during the period.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.